The choice of targeted therapy for patients with metastatic breast cancer is guided by ER, PR, and HER2 status of the primary tumor, despite evidence indicating that hormone receptor status may change during tumor progression [4, 6, 11]. This evidence concerns the gene ERBB2 and neoplasm.